Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 3/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
| ▸ | F7 | P08709 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | F3 | P13726 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30155019 | 1.00 | CA1 (0.51) | CA1CA2CA9CA12CYP19A1 | |
| Sulfuric Acid SCHEMBL1491064 | 0.95 | CA1 (0.48) | CA1CA2CA9CA12CYP19A1 | |
| Succinic Acid SCHEMBL9706877 | 0.90 | CTNNB1 (0.45) | CA1CA2CA9CA12CYP19A1 | |
| SCHEMBL1650349 | 0.83 | CA12 (0.49) | CA1CA2CA9CA12CYP19A1 | |
| SCHEMBL8990514 | 0.83 | EPHX2 (0.53) | CA1CA2CA9CA12CYP19A1 | |
| SCHEMBL9275073 | 0.81 | CYP19A1 (0.47) | CA1CA2CA9CA12CYP19A1 | |
| SCHEMBL4414373 | 0.81 | HDAC1 (0.52) | CA1CA2CA9CA12CYP19A1 | |
| SCHEMBL5918472 | 0.79 | CYP19A1 (0.55) | CA1CA2CA9CA12CYP19A1 | |
| SCHEMBL27528543 | 0.79 | CA12 (0.48) | CA1CA2CA9CA12CYP19A1 | |
| SCHEMBL2670006 | 0.76 | CA12 (0.46) | CA1CA2CA9CA12CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992012713-A1 | COMPOSITIONS | GLAXO GROUP LIMITED (GB) | 1992-08-06 | — | — | WO | claimed |
| EP-0147107-A1 | Indole derivates | GLAXO GROUP LIMITED (GB) | 1985-07-03 | — | — | EP | claimed |
| CN-102212027-B | Preparation method for sumatriptan | SUZHOU LAKESTAR PHARMATECH CO LTD | 2012-12-12 | — | — | CN | disclosed |
| CN-102212027-A | Preparation method for sumatriptan | SUZHOU LAKESTAR PHARMATECH CO LTD | 2011-10-12 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7862807-B2 | Dendrimers as molecular translocators | UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2011-01-04 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090311249-A1 | Capecitabine Combination Therapy | ARIAD PHARMACEUTICALS, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20080221020-A1 | Dendrimers as Molecular Translocators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-11 | — | — | US | disclosed |
| EP-1833824-A1 | 3-CYCLOALKYLCARBONYL INDOLES AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1545462-A4 | DENDRIMERS AS MOLECULAR TRANSLOCATORS | UNIV CALIFORNIA (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-1998011066-A1 | POLYDITHIOCARBAMATE-CONTAINING MACROMOLECULES AND THE USE THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | MEDINOX, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998009626-A1 | METHODS FOR IN VIVO REDUCTION OF IRON LEVELS AND COMPOSITIONS USEFUL THEREFOR | MEDINOX, INC. (US) | 1998-03-12 | — | — | WO | disclosed |
| WO-1997018805-A1 | COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS | MEDINOX, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
| EP-0697869-A1 | TRANSDERMAL THERAPEUTIC SYSTEMS FOR THE ADMINISTRATION OF SEROTONIN AGONISTS | LTS Lohmann Therapie-Systeme GmbH & Co. KG (DE) | 1996-02-28 | — | — | EP | disclosed |
| WO-1996001106-A1 | USE OF PHARMACEUTICAL AGENTS FOR ALLEVIATION OR TREATMENT OF THE IMMUNE DYSFUNCTION RELATED TO INFECTION WITH HUMAN IMMUNODEFICIENCY VIRUSES (HIV) OR RELATED VIRUSES | HOFMANN BO ARNE (DK) | 1996-01-18 | — | — | WO | disclosed |
| EP-0655912-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF ELEVATED INTRAOCULAR PRESSURE | GLAXO GROUP LIMITED (GB) | 1995-06-07 | — | — | EP | disclosed |
| WO-1994026270-A1 | TRANSDERMAL THERAPEUTIC SYSTEMS FOR THE ADMINISTRATION OF SEROTONIN AGONISTS | LTS LOHMANN THERAPIE-SYSTEME GMBH & CO. KG (DE) | 1994-11-24 | — | — | WO | disclosed |
| WO-1994003162-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF ELEVATED INTRAOCULAR PRESSURE | GLAXO GROUP LIMITED (GB) | 1994-02-17 | — | — | WO | disclosed |
| WO-1992012712-A1 | COMPOSITIONS | GLAXO GROUP LIMITED (GB) | 1992-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311249-A1 | Capecitabine Combination Therapy | RICTOR, MTOR, EIF4E | CA1 4199/4885CA2 3100/4885CA9 1468/4885 |
| US-20080221020-A1 | Dendrimers as Molecular Translocators | SLC29A1, SLC29A2, TSPO | CA1 4290/4885CA2 2620/4885CA9 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.